Expanded indication makes SIR-Spheres the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer
Sirtex Medical, a leading manufacturer of interventional oncology solutions, announced that the U.S. Food and Drug Administration (FDA) approved SIR-Spheres Y-90 resin microspheres for the treatment of unresectable hepatocellular carcinoma (HCC) in the United States. With this approval, SIR-Spheres is the only radioembolization therapy approved for the treatment of both metastatic colorectal cancer (mCRC) of the liver and HCC in the U.S.
Health Technology Insights: Britt Vitalone Joins Align Technology Board of Directors
HCC is the most common form of liver cancer in adults in the U.S., according to the American Cancer Society. Radioembolization–commonly referred to as selective internal radiation therapy (SIRT)–with SIR-Spheres uses personalized dosimetry to deliver the optimal dose of radiation directly to tumors in patients with HCC. This approval gives clinicians expanded flexibility in selecting a liver-directed therapy that aligns with patient-specific needs and treatment goals.
“The expanded indication makes SIR-Spheres the only Y-90 treatment approved in the U.S. for both HCC and mCRC,” said Matt Schmidt, CEO of Sirtex. “This milestone reflects our ongoing commitment to delivering flexible, personalized therapies—with multiple dose options available daily—that empowers physicians to treat patients when and where it works best.”
Health Technology Insights: Microsoft’s Email Encryption Behavior May Violate HIPAA, New Paubox Report Warns
This regulatory milestone is supported by results from the DOORwaY study, a prospective, multicenter, open-label clinical trial evaluating the safety and efficacy of SIR-Spheres in treating HCC. The study enrolled 100 patients across 18 U.S. centers, with 65 patients included in the interim primary efficacy cohort. DOORwaY met its prespecified co-primary endpoints, demonstrating a best overall response rate (ORR) of 98.5% as assessed by independent central review. All evaluable patients demonstrated a response, indicating a 100% local tumor control rate. Additionally, the median duration of response (DoR) exceeded 300 days. These findings highlight SIR-Spheres as a highly effective liver-directed therapy with a favorable safety profile.
“This study moves the field of radioembolization forward with reproducible dosimetry outcomes and a strong safety profile linked to very positive clinical results,” said Dr. Armeen Mahvash, Interventional Radiologist at MD Anderson Cancer Center and Co-Principal Investigator of the DOORwaY Study. “This will give multidisciplinary care teams the confidence to recommend SIR-Spheres for HCC treatment.”
Health Technology Insights: Nuclear Care Partners Backs Bipartisan Bill for Energy Workers’ Care
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
